Eton Pharmaceuticals stock gets 8.6% ownership filing
Published on 11/17/2026 at 01:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOwnership filing adds investor focus
- EcoR1 Capital and Oleg Nodelman reported shared voting and dispositive power in Eton Pharmaceuticals.
- The filing identifies the investment as held in the ordinary course and not for control purposes.
- Eton develops and commercializes therapies for rare diseases through licensing, acquisitions and internal development.
Eton Pharmaceuticals faces a fresh ownership disclosure after an amended Schedule 13G/A filed on Monday, November 16, 2026. EcoR1 Capital, LLC and Oleg Nodelman each reported beneficial ownership of 2,470,920 common shares, while EcoR1 Capital Fund Qualified, L.P. reported 2,286,883 shares.
The filing lists September 30, 2026, as the date of the event requiring the statement. It also says the reporting persons hold the shares in the ordinary course and do not intend to influence control of Eton. The filing was accepted by the U.S. Securities and Exchange Commission on November 16.
Shared voting power shapes disclosure
EcoR1 Capital and Nodelman reported shared voting and dispositive power, with no sole voting or dispositive power. The filing states that the reported ownership percentages are based on 28,842,215 common shares outstanding as of November 2, according to Eton's quarterly filing.
StockTitan's filing page reproduces the Schedule 13G/A and its ownership details. The disclosure gives investors a clearer view of a significant institutional holding, while its stated passive status limits the filing's direct implication for corporate control.
Rare-disease portfolio drives business
Eton Pharmaceuticals develops, acquires and commercializes therapies for patients with rare diseases. The company has a diversified pipeline across multiple therapeutic areas and focuses on moving products from development to patients. Its strategy combines licensing, acquisitions and internal development, positioning Eton as a specialized rare-disease operator rather than a broad-based pharmaceutical group.
Eton Pharmaceuticals at a glance
- Company: Eton Pharmaceuticals, Inc.
- ISIN: US29772L1089
- Ticker: ETON
- Primary exchange: Nasdaq
- Business: Rare-disease therapies
Eton's shares are part of the U.S. equity-market environment represented by the S&P 500 market environment.
More news and analyses on Eton Pharmaceuticals stock are available on the company topic page.
